AHZ is 2 companies -why not split into 2?, page-6

I must admit that fully funding what (at present) amounts pretty much to a research division, makes our bottom line look less attractive than it could be. Pictures of the professor on some ski slope don't do much for me -- but addressing a conference to announce a cure for herpes would. If the company was only focused on further developing the hospital infusion equipment side and fast tracking uses for our world leading ADAPT technology, then I think that our rapid growth would be almost a certainty and I would be assured of finally getting my investment back.
Overall; I feel that retaining the vax side of this company is a bit like gripping a wolf by the ears ....... don't want to hold it but don't dare to let go.